Skip to main content

Research Repository

Advanced Search

All Outputs (2)

Multi-omic approach identifies hypoxic tumor-associated myeloid cells that drive immunobiology of high-risk pediatric ependymoma. (2023)
Journal Article
Griesinger, A. M., Riemondy, K., Eswaran, N., Donson, A. M., Willard, N., Prince, E. W., Paine, S. M. L., Bowes, G., Rheaume, J., Chapman, R. J., Ramage, J., Jackson, A., Grundy, R. G., Foreman, N. K., & Ritzmann, T. A. (2023). Multi-omic approach identifies hypoxic tumor-associated myeloid cells that drive immunobiology of high-risk pediatric ependymoma. iScience, 26(9), Article 107585. https://doi.org/10.1016/j.isci.2023.107585

Ependymoma (EPN) is a devastating childhood brain tumor. Single-cell analyses have illustrated the cellular heterogeneity of EPN tumors, identifying multiple neoplastic cell states including a mesenchymal-differentiated subpopulation which characteri... Read More about Multi-omic approach identifies hypoxic tumor-associated myeloid cells that drive immunobiology of high-risk pediatric ependymoma..

Activated tissue resident memory T-cells (CD8+CD103+CD39+) uniquely predict survival in left sided “immune-hot” colorectal cancers (2023)
Journal Article
Talhouni, S., Fadhil, W., Mongan, N. P., Field, L., Hunter, K., Makhsous, S., Maciel-Guerra, A., Kaur, N., Nestarenkaite, A., Laurinavicius, A., Willcox, B. E., Dottorini, T., Spendlove, I., Jackson, A. M., Ilyas, M., & Ramage, J. M. (2023). Activated tissue resident memory T-cells (CD8+CD103+CD39+) uniquely predict survival in left sided “immune-hot” colorectal cancers. Frontiers in Immunology, 14, Article 1057292. https://doi.org/10.3389/fimmu.2023.1057292

Introduction: Characterization of the tumour immune infiltrate (notably CD8+ T-cells) has strong predictive survival value for cancer patients. Quantification of CD8 T-cells alone cannot determine antigenic experience, as not all infiltrating T-cells... Read More about Activated tissue resident memory T-cells (CD8+CD103+CD39+) uniquely predict survival in left sided “immune-hot” colorectal cancers.